Wrong again my friends
The value is in the developed drug and what it can be licensed for to big pharma
As indicated in webinar, this was the company Jackie was talking about at the AGM in November 2023, having scoured the earth looking for a solution to it's molecule using Starpharma's platform in ADC's
So in the 3-4 year development cycle getting it to POC and then on selling to big pharma we could be talking billions of dollars
22.5% of billions of dollars is a lot of monet
And as the CEO of Patalion mentioned, there could be inflection points along the way which might accelerate exit
All in all a very good announcement yesterday
I look forward to many more that will add value to Starpharma
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-77
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $47.38M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $43.20K | 391.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20946 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 104392 | 6 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
11.3¢ |
Change
0.000 ( 2.17 %) |
||||
| Open | High | Low | Volume | ||
| 11.3¢ | 11.3¢ | 11.0¢ | 82292 | ||
| Last updated 15.58pm 31/05/2024 ? | |||||
| SPL (ASX) Chart |